A new PeerLINC global learning session highlights how the BDLLfxC regimen is opening the door to more inclusive, family-centered DR-TB care—bringing shorter, safer treatment to groups who have not yet been able to realize the full benefits of new, shorter regimens.

Born from the Philippines’ early leadership in rolling out six-month DR-TB regimens, PeerLINC has rapidly grown into a global hub where countries learn directly from one another to modernize TB care. Its peer-to-peer model is reshaping how technical assistance is delivered and helping nations to quickly bring shorter, safer treatments to those who need them.

As the NC-009 trial points to a powerful new TB regimen, the results emphasize why platforms like PeerLINC are essential for translating scientific progress into timely, scalable access worldwide.

At the 2025 Union Conference, PeerLINC brought together countries to share early outcomes and lessons from adopting six-month DR-TB regimens—showcasing growing global progress and the power of peer learning in modernizing TB care.

After the PeerLINC Regional Training in Manila, Dr. Kenneth Sodeng launched echo sessions at ANGAU Memorial Provincial Hospital in Lae to strengthen his team’s confidence in managing drug-resistant TB with WHO-aligned guidance. By adapting the materials to local constraints, he is turning a single training into ongoing peer learning and improved care.

Health leaders from 11 countries across the Pacific Islands and Somalia gathered in Manila from for a regional training led by PeerLINC. The week-long program enhanced the capacity of National Tuberculosis Program (NTP) teams to implement shorter, all-oral treatment regimens for drug-resistant tuberculosis (DR-TB) in line with the World Health Organization (WHO) recommendations.

A programmatic review of more than 200 people in Nigeria treated with BPaL/M, found 89% treatment success rates among with MDR/RR-TB and 100% for the smaller pre-XDR cohort. PeerLINC has helped to close critical training gaps in the country, which help to support effective and widespread scale-up of the regimens.

PeerLINC has expanded its training portfolio, adding four new modules, which countries participating in training programs can request. Topics of these new modules include appropriate use of alternate six- and nine-month regimens, co-management of TB and diabetes, and best practices in TB preventative therapy.

A new study confirms that six-month BPaL/M regimens for drug-resistant TB save lives and money. Compared to longer treatments, they cut costs per cure, boost completion rates, and are projected to deliver nearly US$1 billion in economic benefits in South Africa and US$800 million in the Philippines within five years.

Lupin Limited, a leading pharmaceutical company based in India, received World Health Organization (WHO) prequalification for its 200mg pretomanid tablet. This achievement adds another manufacturer to the market for a critical component of WHO-endorsed six-month drug-resistant TB treatments. Having multiple producers strengthens the global supply of pretomanid, ensures consistent quality, and drives competition that helps further lower costs.